A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes
Recruiting now · Phase 1
Conditions studied: Type 2 Diabetes
In brief
The objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of SHR-3167 at steady state in subjects with type 2 diabetes.
Key facts
- Study ID
- NCT07032688
- Run by
- Jiangsu HengRui Medicine Co., Ltd.
- People needed
- 55
- Starts
- 2025-08-11
- Expected to finish
- 2027-04-01
- Last updated by the study team
- 2026-04-17
Who can join
Age: 18 and older, up to 59. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Informed consent obtained before any trial-related activities.
- Age 18\~59 years at screening (including cut-off values at both ends).
- Confirmed diagnosis of type 2 diabetes mellitus ≥ 6 months before screening.
- Female subjects of childbearing potential and their partners are male subjects of childbearing potential, who have no fertility plan and agree to take high-efficiency contraceptive measures within 3 months after signing the informed consent form and have no plans to donate eggs/sperm; Female subjects of childbearing potential have a negative pregnancy test during the screening period and are not lactating.
You may not qualify if…
- Poor blood pressure control at screening.
- Known or suspected allergy to investigational drug products or related products; or a history of multiple and/or severe allergies to drugs or foods.
- Serious cardiovascular and cerebrovascular diseases within 6 months prior to screening.
- Positive test for hepatitis B surface antigen (HBsAg), HIV antibody, treponema pallidum specific antibody, or hepatitis C virus antibody; or the investigator judges that the subject is in the incubation or active phase of the above infection.
- Malignancy or history of malignancy within 5 years prior to screening.
- Participation in any clinical trial of an approved or unapproved investigational drug/medical device within 90 days prior to screening.
- Any other condition judged by the investigator to be likely to affect the subject's safety or interfere with the evaluation of trial results.
Where it is running
- West China Hospital of Sichuan University — Chengdu, Sichuan, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.